Advertisement


Rent Increase Survey

Have you submitted your latest rent increase data to the rent increase survey?

BioTime to Market Stem Cells in China, Taiwan

BioTime, an Alameda-based biotechnology company, announced this week that it will market its stem cell lines in Asia, through an agreement with Shanghai Genext Medical Technology Company.

The agreement permits Genext to market BioTime’s ACTCellerate cell lines to medical and biological research communities in China, Taiwan, Hong Kong and Macau. Genext will have to hit annual milestones to maintain exclusive rights to market BioTime’s products.

In a statement, Michael D. West, Ph.D., BioTime’s CEO, said, “Genext is a leader in the marketing and distribution of products and services in the field of stem cell technology, organ transplantation, and regenerative medicine. With over 400 hospitals and 2,500 stem cell researchers in their distribution network, Genext is the ideal partner for introducing our novel cell lines, media, and related reagents for rapidly growing research markets in Asia.”

Comments are closed.

  • Can the Police Prevent the Next Charlottesville? https://t.co/BTWZ8fFU0z ,
  • City Moves to Adapt Former Enlisted Quarters to a Tech Campus https://t.co/3DtmaYt1GC ,
  • https://t.co/onC6JrxE9U ,
  • Can the Police Prevent the Next Charlottesville? https://t.co/BTWZ8fFU0z ,
  • #alameda Everyone belongs here vigil ,

Directories